Drug Pipeline

NALIRIFOX Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
4
Recruiting
4
Top Sponsors
Active Studies by Phase
Phase 2
2
Phase 1/2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT07163273 Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic… Pancreatic Ductal Adenocarcinoma Recruiting
NCT05851924 A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic… Pancreatic Ductal Adenocarcinoma Recruiting
Phase 1/2
NCT06483555 Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel Pancreatic Adenocarcinoma Recruiting
Phase 1
NCT07030283 Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With… Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting
Sponsors Running NALIRIFOX Trials
Memorial Sloan Kettering Cancer Center (1) UNC Lineberger Comprehensive Cancer Center (1) University of Colorado, Denver (1) Northwell Health (1)
Disease Areas
Pancreatic Cancer (4)
Get alerts when NALIRIFOX trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free